期刊文献+

吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察 被引量:8

Clinical observation of Gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法:35例65岁以上NSCLC患者均接受国产吉西他滨(泽菲)800~1000mg/m2,第1、8天静脉滴注,每21~28天为1个周期,至少2个周期。结果:35例患者均可评价疗效,其中,完全缓解0例,部分缓解8例,有效率为22.86%(8/35)。中位疾病进展时间(TTP)为5.2个月,中位生存期为7.2个月,1年生存率为28.6%。主要毒副作用为白细胞及血小板下降,多为Ⅰ~Ⅲ度,可以耐受。结论:吉西他滨单药治疗老年晚期NSCLC安全有效,不但延长患者的生存时间,且可改善生活质量,毒副作用可以耐受。 Objective: To observe the clinical efficacy and toxicity of Gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer (NSCLC). Methods: 35 patients aged over 65 with advanced non-small cell lung cancer received Gemcitabine 800-1 000 mg/m^2 on d1,8 intravenously. Repeated every 21-28 days and with at least 2 cycles. Results: In the 35 evaluable cases CR was observed in 0 case and PR 8 cases ,the total response rate was 22.86% (8/35), Median time to progression (TTP) of all the patients was 5.2 months, median survival time was 7.2 months and 1 year suruival rate was 28.6%. The main toxicities were leucopenia and thrombocytopenia, but the most were grade Ⅰ -Ⅲ. They were tolerable. Conclusion: Gemcitabine monotherapy is effective and safe in the treatment of elder advanced NSCLC. It prolong the survival time and improve the quality of life in patients with NSCLC. The toxieitits were well tolerated.
出处 《中国医药导报》 CAS 2009年第13期99-100,共2页 China Medical Herald
关键词 吉西他滨 老年 非小细胞肺癌 化疗 Gemcitabine Elder NSCLC Chemotherapy
  • 相关文献

参考文献7

  • 1Bunn PA,Kelly K.New chemotherapeutic agents prolong survival and improve quality of life in non-stroll cell lung cancer:a review d the literature and future directions[J].Clin Cancer Res,1998,4(5):1087-1100.
  • 2NCCN Clinical Practice Guidline in Oncology:Non-small Cell Lung Cancer Vision 2[S].2007.
  • 3Fry WA,Menck HR,Winchester DP,et al.The national cancer data base report on lung cancer[J].Cancer,1996,77(9):1947-1955.
  • 4王燕,张湘茹.老年晚期肺癌的治疗策略[J].癌症进展,2004,2(6):490-492. 被引量:47
  • 5Manegold C,Bergmann B,Chemaissani A,et al.Single agent gemcitabi ne versus cisplatin-etoposide:Warly result of a randomized phase Ⅱ study in locally advanced or metastatic non small cell lung cromer[J].Ann Oncol,1997,8(6):525.
  • 6Ricci S,Antonuzzo A,Galli L,et al.Gemcitabine monotherapy in elder patients with advanced non-small cell lung cancer:a multicenter phase Ⅱ study[J].Lung Cancer,2000,27:75-80.
  • 7Cridelli C,Perrone F,Cigolari S,et al.The MILES (multicenter italian lung cancer in the elder study)phase Ⅲ trial:gemeitabine + vinorelbine vs.vinorelbine and vs.gemeitabine in elderly advanced NSCLC patients[C].Proc Am Soc Clin Oncol,2001,20:308a(Abstr 1230).

二级参考文献18

  • 1[1]Fry W, Phillips, Menck H. Ten-year survey of lung cancer treatment and survival in hospitals in United States. Cancer,1999, 86:1867
  • 2[2]Socinski M. Chemotherapy for stage Ⅳ non-small cell lung cancer: An evidence-based guide for the practicing clinican. Philadelphia: WB Saunders Company, 2001, 307
  • 3[3]Ng R, Boer RD, Park A, et al. Non small cell lung cancer(NSCLC): Are elderly patients being under-treated? ASCO Pro,2004, 7118
  • 4[4]Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage ⅢB or Ⅳ nonsmall cell lung carcinoma triated with carboplatin and paclitaxel. Cancer, 2003, 98(4) :779
  • 5[5]Lebitasy MP, Monnet L, Depierre A, et al. Management of elderly lung cancer patients in France: A national prospective survey by the French intergroup of thoracic oncology (WCT).ASCO Pro, 2004, 8163
  • 6[6]Okamoto H, Kudoh H, Nagatomo A, et al. A combination chemotherapy of carboplatin and irinotecan in elderly patients with small cell lung cancer (SCLC). ASCO Pro, 2004, 7212
  • 7[7]FukudaM, Oka M, SoejimaY, etal. Elderly (≥70)smallcell lung cancer (SCLC) chemotherapy: A phase Ⅰ study of carboplatin (CBDCA) and etoposide (VP-16). ASCO Pro,2004, 7217
  • 8[8]Katz AV, Arruda MT, Yamaguchi JY, et al. Comparative retrospective study between brs supportive care (BSC) versus chemotherapy for elderly patients with NSCLC. ASCO Pro, 2004,7355
  • 9[9]Yau T, Asley S, Smith L, et al. Time and chemotherapy treatments trends in the elderly (age 》 70) with lung cancer in a single UK cancer centre. ASCO Pro, 2004, 7128
  • 10[10]The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with adbanced non-small-cell lung cancer. J Natl Cancer Inst,1999, 91:66

共引文献46

同被引文献61

引证文献8

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部